Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-12

Summit Therapeutics (SMMT)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$249,127,782
Manmeet Soni total, FY2025
Chief Operating Officer, Chief Financial Officer and Directorhighest-paid officer; CEO Mahkam Zanganeh: $246,047,279
CEO (Mahkam Zanganeh) pay percentile vs peers
489:1
CEO-to-median pay ratio
96.22%
Say-on-pay support, latest vote
Companies that benchmark against SMMT
7 companies name SMMT as a compensation peer

Each company listed discloses SMMT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SMMT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Manmeet Soni$616,500$388,395$0$248,101,887$0$0$21,000$249,127,782
Chief Operating Officer, Chief Financial Officer and Director
Mahkam Zanganeh616,500388,3950245,021,3840021,000246,047,279
Co-Chief Executive Officer, President and Director
Robert Duggan000000172,376172,376
Co-Chief Executive Officer and Chairman of the Board of Directors

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Manmeet Soni$249,127,782$4,772,489$23,613,339+244,355,293
Mahkam Zanganeh246,047,2791,161,02120,562,924+244,886,258
Robert Duggan172,376158,6130+13,763

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Manmeet SoniDirector2026-06-04A25,000$14$361,500CommonForm 4 ↗
Mahkam ZanganehDirector2026-06-04A100,000151,460,000Common, indirectForm 4 ↗
Robert W. DugganDirector2026-06-04A100,000151,460,000Common, indirectForm 4 ↗
Manmeet SoniDirector2026-06-04A25,00014360,750CommonForm 4 ↗
Robert W. DugganDirector2026-06-12A3,810,0001349,987,200CommonForm 4 ↗
Mahkam ZanganehDirector2026-06-12A3,810,0001349,987,200Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mahkam ZanganehOption133,3001.29
Manmeet SoniOption825,0003.85
Mahkam ZanganehOption5,994,0991.68
Mahkam ZanganehOption346,5801.06
Mahkam ZanganehOption3,196,0531.68
Manmeet SoniOption7,000,0001.68
Manmeet SoniOption3,732,4001.68
05

Incentive-plan design — the Compensation Discussion & Analysis

We seek to ensure that the total compensation paid to our NEOs is reasonable and competitive. Compensation of our NEOs is structured around the achievement of individual performance, annual Company objectives and key results ( OKRs ) and long-term business objectives, as further described herein.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultant
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-10622,624,32824,445,791101,38396.22%Passed
20252025-06-12607,320,35316,607,648177,55697.34%Passed
20242024-06-14604,242,48215,872,371879,80197.44%Passed
20212021-06-1661,902,91265,33597,47999.89%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1096.22%a
20252025-06-1297.34%b
20242024-06-1497.44%c

a. Approved under the standard stated in the filing — “If you ABSTAIN from voting on this proposal, your abstention will not be counted as a vote cast on Proposal 3 and will have no effect on the outcome of the proposal.”.

b. Approved under the standard stated in the filing — “If you ABSTAIN from voting on this proposal, your abstention will not be counted as a vote cast on Proposal 3 and will have no effect on the outcome of the proposal.”.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)489 : 1
CEO total compensation
Median employee compensation$503,340
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Kenneth A. ClarkIndependent · Lead Independent Director · Compensation (Chair) · Nominating and Corporate Governance (Chair)$0$835,697$0$835,697
Robert BoothIndependent · Audit · Nominating and Corporate Governance0672,7730672,773
Yu (Michelle) XiaNot independent0649,9960649,996
Jeff HuberIndependent · Audit (Chair)86,6000562,5860649,186
Alessandra CesanoIndependent · Nominating and Corporate Governance28,2000611,9810640,181
Mostafa RonaghiIndependent · Audit · Compensation62,9000562,5860625,486
Robert W. DugganEmployee director · Board Chair00000
Manmeet SoniEmployee director00000
Mahkam ZanganehEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)36,700 / 13,000 / 13,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$177,700
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$177,700

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Summit Therapeutics2025Mahkam Zanganeh$616,500$0$245,021,384$0$246,047,279

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Manmeet SoniDEF 14A2026-04-170001599298-26-000029Section “Summary Compensation Table”. As printed: 249,127,782. Filing ↗machine: r10 · c21 · span 391802–391813
2Section 01, Mahkam ZanganehDEF 14A2026-04-170001599298-26-000029Section “Summary Compensation Table”. As printed: 246,047,279. Filing ↗machine: r6 · c21 · span 385284–385295
3Section 01, Robert DugganDEF 14A2026-04-170001599298-26-000029Section “Summary Compensation Table” · page 48. As printed: 172,376. Filing ↗machine: r2 · c21 · span 377893–377900
4Section 07, pay ratioDEF 14A2026-04-170001599298-26-000029Section “CEO Pay Ratio”. As printed: 489 : 1. Filing ↗machine: t18 · r3 · c5 · span 505620–505627
5Section 08, Kenneth A. ClarkDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 835,697. Filing ↗machine: t8 · r2 · c3 · span 298170–298177
6Section 08, Robert BoothDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 672,773. Filing ↗machine: t8 · r3 · c3 · span 299545–299552
7Section 08, Yu (Michelle) XiaDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 649,996. Filing ↗machine: t8 · r5 · c3 · span 302137–302144
8Section 08, Jeff HuberDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 649,186. Filing ↗machine: t8 · r7 · c5 · span 305054–305061
9Section 08, Alessandra CesanoDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 640,181. Filing ↗machine: t8 · r4 · c5 · span 301181–301188
10Section 08, Mostafa RonaghiDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 625,486. Filing ↗machine: t8 · r6 · c5 · span 303771–303778
11Section 08, Robert W. DugganDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 0. Filing ↗
12Section 08, Manmeet SoniDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 0. Filing ↗
13Section 08, Mahkam ZanganehDEF 14A2026-04-170001599298-26-000029Section “Director Compensation”. As printed: 0. Filing ↗
14Section 02, Manmeet Soni 2026-06-04Form 42026-06-040001569769-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Mahkam Zanganeh 2026-06-04Form 42026-06-040001507650-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Robert W. Duggan 2026-06-04Form 42026-06-040001055919-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Manmeet Soni 2026-06-04Form 42026-06-040001569769-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Robert W. Duggan 2026-06-12Form 42026-06-120001055919-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Mahkam Zanganeh 2026-06-12Form 42026-06-120001507650-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
20Section 06, 2026 voteForm 8-K2026-06-120001599298-26-000054Item 5.07 · say-on-pay result. As reported: 96.22% (votes for as printed: 622,624,328). Filing ↗
21Section 06, 2025 voteForm 8-K2025-06-170001599298-25-000116Item 5.07 · say-on-pay result. As reported: 97.34% (votes for as printed: 607,320,353). Filing ↗
22Section 06, 2024 voteForm 8-K2024-06-170001193125-24-162715Item 5.07 · say-on-pay result. As reported: 97.44% (votes for as printed: 604,242,482). Filing ↗
23Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
24Section 09b board cost (computed)ComputedcomputedCash 177,700 + equity 0 + all other 0 = 177,700, summed across the director compensation table rows.machine: formula: Σ = 177,700
25Summit Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-170001599298-26-000029CEO total compensation as printed in Summit Therapeutics's own proxy. As printed: 246,047,279. Filing ↗machine: r6 · c21 · span 385284–385295